102 related articles for article (PubMed ID: 12463140)
1. [Metastatic kidney cancer: new therapeutic approaches].
Negrier S; Mejean A; Oudard S; Escudier B
Prog Urol; 2002 Sep; 12(4):703-8. PubMed ID: 12463140
[TBL] [Abstract][Full Text] [Related]
2. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.
Roigas J; Johannsen M; Ringsdorf M; Massenkeil G
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1449-58. PubMed ID: 17069529
[TBL] [Abstract][Full Text] [Related]
5. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Conclusion and future directions.
Samlowski WE; Vogelzang NJ
Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and vaccine therapy of kidney cancer.
Doehn C; Kausch I; Melz S; Behm A; Jocham D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
10. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
11. New treatments for metastatic kidney cancer.
Mancuso A; Sternberg CN
Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
[TBL] [Abstract][Full Text] [Related]
12. Nephron-sparing surgery for renal cell carcinoma in the solitary kidney.
Berdjis N; Hakenberg OW; Novotny V; Manseck A; Oehlschläger S; Wirth MP
Scand J Urol Nephrol; 2007; 41(1):10-3. PubMed ID: 17366096
[TBL] [Abstract][Full Text] [Related]
13. Debulking nephrectomy in metastatic renal cancer.
Flanigan RC
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
[TBL] [Abstract][Full Text] [Related]
14. Novel antiangiogenic therapies for renal cell cancer.
Gordon MS
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
[TBL] [Abstract][Full Text] [Related]
15. Predicting cancer-control outcomes in patients with renal cell carcinoma.
Karakiewicz PI; Hutterer GC
Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
Kuczyk M; Wegener G; Jonas U
Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136
[TBL] [Abstract][Full Text] [Related]
17. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approaches in metastatic renal cell carcinoma.
Staehler M; Rohrmann K; Bachmann A; Zaak D; Stief CG; Siebels M
BJU Int; 2005 Jun; 95(8):1153-61. PubMed ID: 15877725
[No Abstract] [Full Text] [Related]
19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
[TBL] [Abstract][Full Text] [Related]
20. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives].
Oudard S; Cornu JN; Rouprêt M; Patard JJ
Prog Urol; 2008 Jul; 18 Suppl 4():S77-80. PubMed ID: 18706375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
